<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6511">
  <stage>Registered</stage>
  <submitdate>8/12/2016</submitdate>
  <approvaldate>8/12/2016</approvaldate>
  <nctid>NCT02988960</nctid>
  <trial_identification>
    <studytitle>A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors</studytitle>
    <scientifictitle>A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects With Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002219-16</secondaryid>
    <secondaryid>M15-862</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advance Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABBV-927
Treatment: drugs - ABBV-927
Treatment: drugs - Nivolumab

Experimental: Escalating Arm 1 - ABBV-927 via intravenous administration at escalating dose levels in 28-day dosing cycles (2 doses per cycle).

Experimental: Escalating Arm 2 - ABBV-927 via intratumoral administration at escalating dose levels in 28-day dosing cycles (2 doses per cycle).

Experimental: Escalation Arm 3 - ABBV-927 via intravenous administration at escalating dose levels in combination with nivolumab in 28-day dosing cycles (2 doses per cycle).

Experimental: Expansion Arm A - Additional participants (with squamous cell carcinoma of the head and neck [SCCHN], pancreatic adenocarcinoma, or non-small cell lung cancer [NSCLC]) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-927.

Experimental: Expansion Arm B1, B2 - Additional participants (with cutaneous melanoma or SCCHN) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-927.

Experimental: Expansion Arm C - Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-927 plus nivolumab.


Treatment: drugs: ABBV-927
Intravenous

Treatment: drugs: ABBV-927
Intratumoral

Treatment: drugs: Nivolumab
Nivolumab will be administered according to standard or approved doses and dosing schedules.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>First dose of study drug through at least 100 days after end of treatment or until the start of another anticancer therapy; up to 2 years after last participants first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with nivolumab - The MTD and the RPTD of ABBV-927 when administered as monotherapy or as combination therapy with nivolumab will be determined during the dose escalation phase of the study. Once the RPTD has been determined, the dose expansion portion will begin.</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum observed serum concentration (Cmax) of ABBV-927</outcome>
      <timepoint>Up to 12 weeks after participant's first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to Cmax (Tmax) of ABBV-927</outcome>
      <timepoint>Up to 12 weeks after participant's first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area under the serum concentration-time curve (AUC) of ABBV-927</outcome>
      <timepoint>Up to 12 weeks after participant's first dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Terminal half-life (t1/2) of ABBV-927</outcome>
      <timepoint>Up to 4 weeks after participant's first dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate (ORR) - ORR is defined as the proportion of participants with a confirmed partial or complete response to the treatment</outcome>
      <timepoint>Up to 30 days after and up to 24-month of treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of objective response (DOR) - DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.</outcome>
      <timepoint>Up to 30 days after and up to 24-month of treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment) - CBR defined as the proportion of subjects with a confirmed partial response (PR), complete response (CR), or stable disease for at least 24 weeks to the treatment.</outcome>
      <timepoint>Up to 30 days after and up to 24-month of treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS) - PFS time is defined as the time from the first dose of ABBV-927 to disease progression or death, whichever occurs first.</outcome>
      <timepoint>Up to 30 days after and up to 24-month of treatment period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
             to 1.

          -  Participants have adequate bone marrow, kidney and liver function.

          -  Participants with a history of chronic heart failure or significant cardiovascular
             disease must have an echocardiogram indicating left ventricular ejection fraction
             greater than or equal to 45% within 28 days prior to the first dose of study drug.

          -  Participants must have creatinine clearance greater than or equal to 50 mL/min as
             measured by 24-hour urine or estimated by the Cockcroft-Gault formula.

          -  Participants must have total bilirubin less than or equal to 1.5 times the upper limit
             of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than
             or equal to 2.5 times ULN.

          -  Participants in all monotherapy arms must have an advanced solid tumor that has
             progressed on standard therapies known to provide clinical benefit or the participants
             are intolerant to such therapies.

          -  Participants in all combination therapy arms must have an advanced solid tumor for
             which the indicated standard of care is nivolumab. At the discretion of the Sponsor,
             subjects with an advanced solid tumor which has progressed on an approved
             anti-PD1/anti-PDL1 agent may be enrolled.

          -  The Sponsor may decide to limit the specific tumor types selected or treatment
             settings for specific arms based on evidence gathered.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participant must not have an active or prior documented autoimmune disease in the last
             2 years.

          -  Participant must not have current or prior use of immunosuppressive medication within
             14 days prior to the first dose (with certain exceptions).

          -  Participant must not have a history of primary immunodeficiency, bone marrow
             transplantation, chronic lymphocytic leukemia, solid organ transplantation, or
             previous clinical diagnosis of tuberculosis.

          -  Participant must not have a history of a coagulopathy or a platelet disorder.

          -  Participant must not have a prior grade greater than or equal to 3 immune-mediated
             neurotoxicity or pneumonitis while receiving immunotherapy.

          -  Participant must not have a known uncontrolled malignancy of the central nervous
             system.

          -  Participants in all combination therapy arms must not have a history of exposure to an
             immunotherapy experiencing an immune-mediated adverse event that required permanent
             discontinuation of the immunotherapy.

          -  Female participants must not be pregnant, breastfeeding or considering becoming
             pregnant during the study or for approximately 3 months after the last dose of study
             drug.

          -  Male participants must not be considering fathering a child or donating sperm during
             the study or for approximately 3 months after the last dose of study drug.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>28/02/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>11/09/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Peninsula &amp; South Eastern Haematology and Oncology /ID# 164372 - Frankston</hospital>
    <postcode>3199 - Frankston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and
      pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or
      recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as
      combination therapy with nivolumab in participants with advanced solid tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02988960</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AbbVie Inc</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AbbVie_Call Center</name>
      <address />
      <phone>847-283-8955</phone>
      <fax />
      <email>abbvieclinicaltrials@abbvie.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>